Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03356002 |
|
Recruitment Status :
Recruiting
First Posted : November 29, 2017
Last Update Posted : June 4, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| High Risk (Above Average) Subjects Non Compliant Patients for Colo Rectal Cancer [CRC] Screening Counterindicated Patients for Colonoscopy | Device: C-Scan System | Not Applicable |
The subject will be invited to come to the clinic to sign the Informed Consent Form [ICF] and other related .
The subjects will be connected to the C-Scan Track and following system's activation the subject will be asked to ingest the C-Scan Capsule with some water and contrast media, in the presence of a physician.
Post ingestion, the subject will be discharged home with clear instructions on the procedure. The subject should avoid intensive physical exercise during procedure or any extreme activities. The subject should make an effort to stay at home or other familiar surroundings, and may continue daily activities such mobile/computer/Television use, shower, sleep or eat. Details on allowed and restricted activities are listed in app. 4 The subject will be required to ingest daily dose (3 X 15-17ml) of contrast media, to be consumed three times per day with normal diet. Also on a need based the subject would be provided with laxadine (5 mg tablets) to be ingested according to the doctor recommendation.
During capsule procedure the subjects will be contacted by phone several times daily by the site clinical study team (or by dedicated external trained medical personnel), to assure the subjects well-being and to monitor for any change or discomfort and for procedure progress. Subjects may be also monitored by the technical team (either at home or at the clinic), who may need to examine the system or inquire the subjects about the system visual/auditory indicators.
The subjects will be provided with a dedicated capsule collection kit, to assist the subjects in collecting the capsule. Subjects will be instructed to retrieve the capsule upon excretion.
Capsule procedure is completed upon capsule excretion or system vibro/auditory indication of 'End of Procedure'.
Once the procedure is completed, The C-Scan Capsule and C-Scan Track will be collected from the subject and returned to the sponsor's lab for preliminary analysis.
All subjects will be scheduled for optical colonoscopy to be performed within one month following capsule procedure.
C-Scan Procedure Analysis:
Several (3-6) licensed gastroenterologist physicians, will be trained with reviewing and analyzing C-Scan System scans, to serve as independent reviewers. Each case will be reviewed by 3 independant reviewers. The reviewing forum will be blinded to the FIT and colonoscopy results of the examined patients. Analysis will be performed on a per patient basis for the existence or non-existence of a finding that may be a polyp. This per patient finding will be compared with the FIT, and a colonoscopy will be performed for verification.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 300 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Care Provider, Investigator) |
| Masking Description: | The colonoscopists will be blinded to the C-Scan system results and FIT results and the reviewers of C-Scan system results will be blinded to Fit and colonoscopy results |
| Primary Purpose: | Diagnostic |
| Official Title: | Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects |
| Actual Study Start Date : | January 28, 2018 |
| Estimated Primary Completion Date : | December 30, 2019 |
| Estimated Study Completion Date : | February 26, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: High risk subjects
Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy. Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following: c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms: |
Device: C-Scan System
Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.
Other Name: Colon capsule |
|
Experimental: Average risk
Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy. Average risk based on their age and demographics referred for screening for polyps. |
Device: C-Scan System
Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.
Other Name: Colon capsule |
- Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy [ Time Frame: One year ]Number of polyps detected by the capsule system in various segments of the colon as compared with the results indicated in the report of the follow-up colonoscopy
- Sensitivity and specificity of C-Scan Capsule System in detecting patients with polypoid lesions 6≤x≤9 mm, compared with Optical Colonoscopy [ Time Frame: One year ]Number of polyp specificity of C-Scan Capsule System in detecting patients with polypoid lesions 6≤x≤9 mm detected by the capsule system in various segments of the colon as
- Calculation of the score of the C-Scan system to generate a 3D model of the colon [ Time Frame: One year ]Using the C-Scan View work station, the review will determine the score, on a scale of 1-10, the completeness of the colon model in each case. The average and Standard Deviation [SD] of all results will be calculated
- Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers [ Time Frame: One year ]Each case will be reviewed by 3 independent reviewers who are blinded to the results of the FIT and colonoscopy. Calculate the variance between the results of each reviewer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
- Male or female at the age of 40-80 years old
- Subject provided signed informed consent
Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:
Surveillance - Significant findings in previous optical colonoscopy Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy Diagnostic - Positive FIT test
Diagnostic - one or more of the typical symptoms:
abdominal pain Change in bowel habits Anemia or overt bleeding in stool Significant weight loss
1st degree relatives of CRC subjects Alternatively average risk based on their age and demographics referred for screening for polyps.
Exclusion Criteria:
- Subjects with advanced cancer or other life threatening diseases or conditions
- Subject with known history of dysphagia or other swallowing disorders
- Subject with known history of GI disease or symptoms, such as: Crohn's disease, Colitis, Inflammatory Bowel Disease [IBD], Meckel's Diverticulum, Bowen Hernia, Mega Colon, fistulas or other strictures (doctors' discretion).
- Subject with known motility disorder or Chronic Constipation (less than 3 bowel movements/week)
- Subject with known delayed gastric emptying
- Subject with prior history of abdominal surgery that might cause bowel strictures leading to capsule retention, as determined by physician discretion
- Subject with any condition believed to have an increased risk for capsule retention such as intestinal tumors, radiation enteritis, and incomplete colonoscopies due to obstructions or NSAID enteropathy, as determined by physician discretion
- Subject with a cardiac pacemaker or other implanted electro medical device
- Subjects with known sensitivity to iodine, or with kidney failure
- Subjects with morbid obesity (BMI > 40)
- Subjects with belly / girth circumference > 125 cm
- Subject with any known condition which precludes compliance with study and/or device instructions
- Subject with known condition of drug abuse and/or alcoholism
- Subject who is unable to undergo colonoscopy or bowel preparation necessary for colonoscopy (based on previous attempts or self-declaration)
- Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of child-bearing potential that do not practice medically acceptable methods of contraception)
- Concurrent participation in another clinical trial using any investigational drug or device
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03356002
| Contact: Shlomo Lewkowicz, D.Sc. | +972-52-4747234 | shlomo.lewkowicz@check-cap.com | |
| Contact: Hedva Taanach, RN B.Sc. | +972-52-5380377 | hedva.taanach@check-cap.com |
| Israel | |
| Rambam Medical Center | Recruiting |
| Haifa, North, Israel | |
| Contact: Elizabeth Half, Prof. +9729-73-7064002 E_Half@rambam.health.gov.il | |
| Haemek Medical Center | Recruiting |
| Afula, Israel | |
| Contact: ian ian gralnek, Prof. 04-6495552 ian_gr@clalit.org.il | |
| Soroka Medical Center | Recruiting |
| Be'er Sheva, Israel | |
| Contact: Naim Abu Freha, MD 08-6400251 naimaf@clalit.org.il | |
| Bnai-Zion Medical Center | Recruiting |
| Haifa, Israel | |
| Contact: Tova Rainis, M.D. +972-4-8359426 tovarainis@gmail.com | |
| Contact: Leonid Shpoker, RN +972-4-8359426 | |
| Meir Medical Center | Recruiting |
| Kfar Saba, Israel | |
| Contact: yehuda Ringel, Prof. 09-7472523 udiringel@clalit.org.il | |
| Laniado Medical Center | Terminated |
| Netanya, Israel | |
| Tel Aviv Sorasky Medical Center | Recruiting |
| Tel Aviv, Israel | |
| Contact: Nadir Arber, Prof' +972-3-6974896 | |
| Principal Investigator: Menachem Moskowicz, MD | |
| Study Director: | Boaz Shpigelman | VP R&D |
| Responsible Party: | Ceck Cap Ltd. |
| ClinicalTrials.gov Identifier: | NCT03356002 History of Changes |
| Other Study ID Numbers: |
CL-SY-01-0094 |
| First Posted: | November 29, 2017 Key Record Dates |
| Last Update Posted: | June 4, 2019 |
| Last Verified: | May 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | Preliminary results will be presented in the European Gastro Week Conference [UEGW] on October 2018 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases Colonic Diseases |